Clinical Performance of Three Daily Disposable Silicone Hydrogel Contact Lenses
Launched by JOHNSON & JOHNSON VISION CARE, INC. · Jan 10, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the performance of three different types of daily disposable silicone hydrogel contact lenses to see how well they help people see clearly. The study is currently recruiting participants, and it aims to include adults aged 18 to 40 who regularly use digital devices for several hours each day and are accustomed to wearing silicone hydrogel contact lenses. Eligible participants should have a specific level of vision and meet other criteria regarding their eye health and contact lens usage.
If you decide to join the study, you will wear each of the three types of contact lenses over a set period while researchers track how well they work for you. It’s important to note that some people, such as those with specific eye conditions or those who have recently used certain types of contact lenses, will not be able to participate. Overall, this trial aims to find out which lens option may provide the best vision for users, and your participation could help improve contact lens options for everyone.
Gender
ALL
Eligibility criteria
- Potential subjects must satisfy all of the following criteria to be enrolled in the study:
- • 1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form
- • 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- • 3. Be between 18 and 40 (inclusive) years of age at the time of screening.
- • 4. By self-report, they typically use digital devices for a minimum of 4 hours per day, 5 days per week.
- • 5. In a pre-study screening assessment, they must have a CVS-Q score of 6 or greater.
- • 6. Agree not to participate in other clinical research while enrolled on this study.
- • 7. Own a wearable pair of spectacles, if needed, for distance vision correction (by self-report).
- • 8. By self-report, habitually wear silicone hydrogel soft contact lenses in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 8 hours of wear per day, for at least 4 days per week over the past 4 weeks.
- • 9. Attain a best-corrected logMAR distance visual acuity of at least 0.20 in each eye.
- • 10. Have spherical contact lens prescription in the range -1.00 to -6.00 DS (based on the calculated ocular refraction) in each eye.
- • 11. Have up to a maximum of 1.00 DC of refractive astigmatism (based on the calculated ocular refraction) in each eye.
- Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- • 1. Be currently pregnant or lactating.
- • 2. By self-report, have any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease (e.g. hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g., rheumatoid arthritis), or other diseases, which in the opinion of the investigator is likely to interfere with contact lens wear and/or participation in the study or may pose a risk to study personnel.
- • 3. Have an ocular disorder which would normally contraindicate contact lens wear.
- • 4. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
- • 5. Be currently wearing monovision or multifocal contact lenses.
- • 6. Be currently wearing or have had worn Acuvue® Oasys 1-Day, Dailies® Total1, or Clariti 1-Day lenses during the last 3 months.
- • 7. Have had cataract surgery.
- • 8. Have had corneal refractive surgery.
- • 9. Be using any topical medications such as eye drops or ointments.
- • 10. Have a known hypersensitivity or allergic reaction to sodium fluorescein.
- • 11. Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lens wear. See section 9.1 for additional details regarding excluded systemic medications.
- • 12. Participation in any contact lens or lens care product clinical trial within 2 weeks prior to study enrolment
- • 13. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
- • 14. Have clinically significant (grade 3 or higher on the Efron grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that in the opinion of the investigator would contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
- • 15. Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.
- • 16. They have any corneal distortion resulting from previous hard or rigid lens wear or have keratoconus.
About Johnson & Johnson Vision Care, Inc.
Johnson & Johnson Vision Care, Inc. is a leading global company dedicated to advancing the field of eye health through innovative solutions and research. A subsidiary of Johnson & Johnson, it specializes in the development and manufacturing of contact lenses, surgical products, and vision correction technologies. With a commitment to improving the quality of life for individuals facing vision challenges, the company invests significantly in clinical trials and scientific research to ensure safety, efficacy, and optimal performance of its products. Johnson & Johnson Vision Care, Inc. is renowned for its robust portfolio that combines cutting-edge technology with a patient-centered approach, striving to enhance visual care for people around the world.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manchester, , United Kingdom
Patients applied
Trial Officials
Johnson & Johnson Vision Care, Inc. Clinical Trial
Study Director
Johnson & Johnson Vision Care, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported